S100a4 Antibody

What is S100A4 and why is it a target for antibody development?

S100A4 is a calcium-binding protein with well-established metastasis-promoting activity that plays critical roles in cancer progression and immunosuppression. Its expression strongly correlates with poor prognosis in numerous cancer types . The protein functions both intracellularly and extracellularly, with the extracellular form driving metastasis by affecting the tumor microenvironment and promoting immunosuppression . These properties make S100A4 an attractive target for therapeutic antibody development as blocking its function could potentially inhibit disease progression in multiple conditions by targeting its pathological effects on the tumor microenvironment .

How does S100A4 contribute to disease pathogenesis?

S100A4 contributes to disease pathogenesis through multiple mechanisms. In cancer, it promotes metastasis by affecting the tumor microenvironment, particularly by recruiting inflammatory cells to the primary tumor site . In prostate cancer specifically, S100A4 gene alteration predicts poor response to androgen deprivation therapy and high risk of mortality . In inflammatory conditions such as systemic sclerosis, S100A4 drives fibrosis through activation of fibroblasts and regulation of immune responses . In rheumatoid arthritis, elevated S100A4 levels in plasma and synovial fluid correlate with disease severity and poorer treatment response . The protein activates TLR4 signaling in peripheral blood mononuclear cells, leading to increased inflammatory responses, and enhances monocyte reactivity to stimulation .

How can researchers evaluate S100A4 antibody efficacy in cancer models?

To evaluate anti-S100A4 antibody efficacy in cancer models, researchers should implement a multi-step approach:

• In vitro assessment:

  • Conduct invasion assays with T cells and fibroblasts to measure the antibody's ability to suppress cellular migration

  • Perform cell-based assays to evaluate inhibition of S100A4-induced signaling pathways

  • Test antibody binding specificity using immunofluorescence and Western blotting with appropriate controls (S100A4 +/+ and -/- cells)

• In vivo evaluation:

  • Use experimental metastasis models to assess antibody effects on metastatic burden, particularly in lungs

  • Measure T cell recruitment to primary tumors before and after antibody treatment

  • Analyze changes in tumor microenvironment composition through immunohistochemistry and flow cytometry

  • Quantify survival benefits in treated versus untreated groups

• Biomarker analysis:

  • Monitor circulating S100A4 levels in serum or other body fluids during treatment

  • Evaluate changes in downstream signaling pathways affected by S100A4 inhibition

The antibody's effectiveness can be determined by its ability to block S100A4-mediated effects across these experimental systems.

What evidence supports the role of S100A4 as a predictive biomarker in prostate cancer?

Studies utilizing the DECIPHER genomic test have demonstrated that biopsy S100A4 overexpression predicts poor response to androgen deprivation therapy (ADT) and high mortality risk in radical prostatectomy-treated patients . Analysis of tumor genome data from over 1,000 prostate cancer patients across multiple studies (PRAD/SU2C/FHCRC) has validated the association between S100A4 and aggressive disease progression .

Mechanistically, extracellular S100A4 protein regulates metastasis and promotes aggressive phenotypes by sustaining a chronic inflammatory and immunosuppressive microenvironment in prostatic tissue . Detection of S100A4 in patient specimens can be performed using Immuno-Slot-blot assays of serum or through analysis of tissue samples via standard immunoblot/western blot protocols . This evidence collectively suggests that S100A4 could serve as both a fluid-biopsy biomarker for disease monitoring and a therapeutic target for advanced prostate cancer.

How effective are anti-S100A4 antibodies in treating systemic sclerosis (SSc)?

Anti-S100A4 monoclonal antibodies have demonstrated significant efficacy in treating experimental models of systemic sclerosis. In bleomycin-induced skin fibrosis models and Tsk-1 mice, S100A4 inhibition effectively treated pre-established fibrosis and promoted regression of existing fibrosis . Treatment resulted in:

• Reduced dermal thickening

• Decreased myofibroblast counts

• Diminished collagen accumulation

• Modulation of multiple profibrotic and proinflammatory pathways

Transcriptional profiling revealed that S100A4 inhibition targets multiple pathogenic processes relevant to SSc. In precision-cut SSc skin slices analyzed by RNA sequencing, anti-S100A4 treatment modulated inflammation and fibrosis-relevant gene sets . The antibody affects several downstream targets of S100A4, including AMP-activated protein kinase, calsequestrin-1, and phosphorylated STAT3, with STAT3 inhibition preventing the profibrotic effects of S100A4 on fibroblasts in human skin . These findings strongly support the further development of anti-S100A4 monoclonal antibodies as disease-modifying therapies for systemic sclerosis.

What mechanisms explain S100A4's role in fibrotic diseases, and how do antibodies against it function?

S100A4 promotes fibrosis through several key mechanisms:

• Macrophage-mediated pathways: Alveolar macrophages polarized by IL-4 increase S100A4 expression, which activates lung fibroblasts and contributes to disease progression . S100A4-deficient mice are protected from lung fibrosis, and this protection can be reversed through adoptive transfer of S100A4 wild-type macrophages, demonstrating its causal role in fibrosis development .

• Fibroblast activation: S100A4 directly promotes invasive growth of human and mouse fibroblasts, contributing to fibrotic tissue remodeling . The protein induces myofibroblast differentiation and increases collagen production.

• Inflammatory cell recruitment: S100A4 facilitates recruitment of T cells and other inflammatory cells to sites of tissue injury, perpetuating the inflammatory-fibrotic cycle .

Anti-S100A4 antibodies function by binding to extracellular S100A4, preventing its interaction with cellular receptors. The antibody recognition site typically overlaps with the target binding interface of human S100A4, effectively neutralizing its biological activity . This blockade prevents S100A4-mediated signaling that would otherwise promote fibroblast activation, inflammatory cell recruitment, and extracellular matrix deposition – key processes in fibrotic disease progression.

What methods can be used to detect and analyze S100A4 protein in experimental settings?

Researchers can employ multiple complementary techniques to detect and analyze S100A4 protein:

• Detection in cell culture supernatants and body fluids:

  • Immuno-Slot-blot assay: Grow cells to 80% confluence, wash with PBS twice, culture in serum-free media for 24h, collect media, and analyze using slot-blot apparatus with nitrocellulose membrane following standard immunoblot protocols .

  • ELISA: Can be used for quantitative measurement of S100A4 in serum, plasma, or culture supernatants.

• Detection in cell and tissue lysates:

  • Western blotting: Prepare total cell extracts from different cell lines, separate proteins by SDS-PAGE, transfer to membrane, and probe with anti-S100A4 antibodies .

  • Immunoprecipitation: For evaluating protein-protein interactions involving S100A4.

• Tissue and cellular localization:

  • Immunofluorescence staining: Fix cells or tissue sections, permeabilize if assessing intracellular S100A4, block non-specific binding, and incubate with anti-S100A4 antibodies followed by fluorescently-labeled secondary antibodies .

  • Immunohistochemistry: For detecting S100A4 in formalin-fixed, paraffin-embedded tissue sections.

• Functional assays:

  • Invasion assays: To assess the effect of S100A4 or anti-S100A4 antibodies on cellular invasion .

  • T-cell recruitment assays: To evaluate the impact on immune cell trafficking and recruitment.

Appropriate controls, including S100A4-deficient cells or tissues, should be included to verify antibody specificity.

How can researchers evaluate cross-reactivity and specificity of anti-S100A4 antibodies?

Thorough evaluation of antibody cross-reactivity and specificity is essential for reliable research outcomes. Researchers should:

• Test with positive and negative control samples:

  • Compare reactivity between S100A4-positive and S100A4-negative cell lines (e.g., S100A4 +/+ and S100A4 -/- MEFs)

  • Assess immunofluorescence staining patterns, with S100A4-deficient cells showing no staining if the antibody is specific

• Evaluate species cross-reactivity:

  • Test antibody recognition across different species (human vs. mouse S100A4)

  • Document any species-specific recognition patterns (some antibodies recognize only mouse protein while others recognize both human and mouse S100A4)

• Assess unintended cross-reactivity:

  • Perform western blots to identify any unrelated proteins recognized by the antibody

  • Look for bands at molecular weights other than S100A4's expected size (some antibodies may recognize unidentified proteins at ~55 and 90 kDa)

• Validate across multiple cell lines:

  • Test antibody recognition in diverse cancer cell lines (e.g., breast cancer, colon cancer)

  • Compare staining patterns and intensity across different tissue types

Antibodies showing minimal cross-reactivity with unrelated proteins and consistent recognition patterns across appropriate controls are preferred for research applications.

How does S100A4 function as a mucosal adjuvant, and what are its applications in vaccine development?

S100A4 has demonstrated robust mucosal adjuvant activity for co-administered antigens, with significant potential for vaccine development, particularly against respiratory pathogens. When administered intranasally with antigens such as ovalbumin or SARS-CoV-2 spike protein, S100A4:

• Prolongs nasal residence of delivered antigens, enhancing antigen presentation

• Promotes migration of antigen-presenting cells

• Induces strong germinal center responses, observable by both microscopy and mass spectrometry

• Effectively augments antigen-specific humoral immune responses both mucosally and systemically

• Stimulates antigen-specific cytotoxic T cell responses in the lungs

Importantly, these immune responses remain sustained for longer than 6 months, with antibody levels in serum, lung exudate, broncho-alveolar lavage fluid, vaginal lavage, and feces remaining high long after immunization . Unlike some other mucosal adjuvants, S100A4 does not induce olfactory bulb inflammation after nasal delivery, addressing a key safety concern for nasal vaccination .

These properties make S100A4 a promising adjuvant candidate for respiratory mucosal vaccines, including those targeting SARS-CoV-2 and other pathogens that infect via the respiratory tract.

What are the key considerations when designing experiments to evaluate anti-S100A4 antibody effects on inflammatory signaling pathways?

When designing experiments to evaluate anti-S100A4 antibody effects on inflammatory signaling pathways, researchers should consider:

• Receptor targeting and specificity:

  • S100A4 interacts with multiple receptors, including TLR4, which mediates inflammatory responses in conditions like rheumatoid arthritis

  • Experiments should assess whether antibodies block specific receptor interactions or broadly neutralize S100A4

• Cell type-specific responses:

  • Different immune cell populations respond distinctly to S100A4 stimulation

  • Experiments should include multiple relevant cell types (macrophages, dendritic cells, T cells, fibroblasts) to comprehensively assess antibody effects

• Downstream signaling analysis:

  • Evaluate effects on key pathways including STAT3 phosphorylation, which has been validated as a downstream target of S100A4 in fibrosis

  • Assess changes in inflammatory cytokine production (IL-1β, IL-6, TNFα) following antibody treatment

• Temporal considerations:

  • Design time-course experiments to distinguish between immediate and delayed effects on signaling pathways

  • Consider long-term treatment protocols to evaluate sustained immunomodulatory effects

• In vivo validation:

  • Complement in vitro signaling studies with appropriate disease models

  • Use transcriptional profiling to identify global changes in inflammatory gene expression patterns following antibody treatment

By systematically addressing these considerations, researchers can gain comprehensive insights into how anti-S100A4 antibodies modulate inflammatory signaling networks in different pathological contexts.